<DOC>
	<DOCNO>NCT00098826</DOCNO>
	<brief_summary>Phase I trial study effectiveness SB-715992 treating patient acute leukemia , chronic myelogenous leukemia , advance myelodysplastic syndrome . Drugs use chemotherapy , SB-715992 , work different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>SB-715992 Treating Patients With Acute Leukemia , Chronic Myelogenous Leukemia , Advanced Myelodysplastic Syndromes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) SB-715992 give daily x 3 infusion patient acute leukemia . II . To obtain pharmacokinetic study SB-715992 give 3 consecutive day schedule every 3 week . III . To describe treatment-related dose-limiting toxicity SB-715992 patient acute leukemia . IV . To describe anti-leukemia activity SB-715992 . V. To correlate treatment-related toxicity pharmacokinetic study SB-715992 . SECONDARY OBJECTIVES : I . To validate KSP major target SB-715992 determining impact drug treatment cytoskeletal morphology peripheral blood mononuclear cell circulate leukemic blast . II . To determine expression tubulin isoforms KSP leukemic blast explore possible relationship gene expression response SB-715992 . OUTLINE : This dose-escalation , multicenter study . Induction chemotherapy : Patients receive SB-715992 IV 1 hour day 1-3 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Consolidation chemotherapy : Patients achieve complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) induction chemotherapy receive 4 additional course SB-715992 beyond CR , PR , SD . Cohorts 3-6 patient receive SB-715992 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 9 patient treated MTD . Patients follow 6 week . PROJECTED ACCRUAL : Approximately 15-30 patient accrue study within 7.5-15 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<criteria>Patients must acute myelogenous acute lymphoblastic leukemia refractory primary standard induction therapy ; relapsed/refractory acute leukemia ; chronic myelogenous leukemia blast crisis eligible diagnosis fail aggressive induction chemotherapy ( provide refractory imatinib ) ; acute leukemia secondary preexisting hematologic condition prior chemotherapy eligible diagnosis fail aggressive induction chemotherapy , advance myelodysplastic syndrome ( RAEB RAEB2 provide neutropenic transfusion dependent ) ; patient denovo acute leukemia eligible aggressive standard induction chemotherapy due advance age serious comorbid medical psychiatric condition , patient age 60 denovo AML unfavorable cytogenetics At least 2 week must elapse completion recent cytotoxic chemotherapy , biologic therapy except hydroxyurea corticosteroid Imatinib ( 24 hour ) ; patient previously receive autologous stem cell transplant allow provide minimum 3 month elapse transplant ( T0 ) patient recover transplant associated toxicity ; patient prior allogeneic stem cell transplant eligible ; minimum five day must elapse since administration granulocyte granulocytemacrophage colonystimulating factor minimum 2 week Neulasta ; minimum 2 week since administration gemtuzumab , ozogamicin ( Mylotarg ) , minimum 4 week prior investigational agent ECOG performance status = &lt; 2 ( Karnofsky &gt; = 50 % ) Life expectancy least 4 week Direct serum bilirubin = &lt; 1.5 mg/dl AST ( SGOT ) /ALT ( SGPT ) &lt; 3 X institutional upper limit normal Creatinine = &lt; 1.5 X institutional upper limit normal The effect SB715992 develop human fetus unknown ; reason mitotic inhibitor know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients may receive investigational agent within 28 day study entry Patients may receive anticancer therapy ( cytotoxic , biologic , radiation , hormonal replacement ) study Prohibited medication : SB715992 moderate significant vitro inhibitor CYP3A4 ; follow list medications/substances moderate significant inhibitors/inducers CYP3A4 , administer concomitantly SB715992 , may alter study drug exposure ; use medications/substances within 14 day ( &gt; = 6 month amiodarone ) prior administration first dose SB715992 discontinuation study prohibit Inhibitors CYP3A4 : Antibiotics : clarithromycin , erythromycin , troleandomycin Antifungals : itraconazole , ketoconazole , fluconazole ( dose &gt; 200 mg/day ) , voriconazole Antidepressants : nefazodone , fluvoxamine Calcium channel blocker : verapamil , diltiazem Miscellaneous : amiodarone* , grapefruit juice , bitter orange ; *use amiodarone within 6 month prior administration first dose SB715992 prohibit Inducers CYP3A4 : Anticonvulsants : phenytoin , carbamazepine , phenobarbital , oxcarbazepine Antibiotics : rifampin , rifabutin , rifapentine Miscellaneous : St. John 's wort , modafinil Patients suspect proven CNS leukemia ( diagnostic lumbar puncture require enrollment ) History allergic reaction attribute compound similar chemical biologic composition SB715992 Uncontrolled intercurrent illness include , limited ongoing active poorly control infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , poorly control pulmonary disease psychiatric illness/social situation would limit compliance study requirement Patients preexist neuropathy grade 2 high eligible participate Pregnant woman exclude study SB715992 mitotic inhibitor potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother SB715992 , breastfeed discontinue mother treated SB715992 Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy ; therefore , HIVpositive patient exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>